索比尼尔，Sorbinil；≥98% (HPLC)

Sorbinil has been used as an aldose reductase inhibitor in diabetic rats as a positive control group.[1]

Sorbinil may be used in cell signaling and neuroscience studies.

 

Sorbinil decreases the level of sorbitol in red blood cells and increases the velocity of nerve conduction. It maintains the myo-inositol content in the nerve and prevents the reduction of sodium-potassium ATPase activity.[2] This action is beneficial in providing symptomatic relief in patients with diabetic neuropathy.[3]

Sorbinil is an inhibitor of Aldose Reductase (AR). AR family members AKR1B1 and AKR1B10 have additionally been shown to play roles in inflammation and cancer.

 

This compound is featured on the Dopamine and Norepinephrine Metabolism page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Pfizer. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.